Brandi Roberts
CIK: 0001516354
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Sep 25, 2026DFTX
Definium Therapeutics, Inc.
Sale(S)Direct3.4K shares at avg. $36.57$123K - Sep 14, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct125K shares- - Aug 12, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct62.5K shares- - Jun 25, 2026DFTX
Definium Therapeutics, Inc.
Sale(S)Direct3K shares at avg. $45.03$136K - Jun 22, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct62.5K shares- - Feb 3, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct150K shares- - Jun 2, 2025MNMD
Mind Medicine (MindMed) Inc.
Award(A)DirectStock Option (Right to Buy)
500K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectRestricted Stock Unit
7.9K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
139.4K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
90K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
119.7K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
90.6K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectRestricted Stock Unit
15.1K shares- - Oct 25, 2024LBPH
Longboard Pharmaceuticals, Inc.
Award(A)DirectRetention Restricted Stock Units
7.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 25, 2026 |  DFTX Definium Therapeutics, Inc. | Sale(S) | 3,377 | $36.57 | $123,497 | Direct |
| Sep 14, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 125,000 | - | $0 | Direct |
| Aug 12, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 62,500 | - | $0 | Direct |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Sale(S) | 3,013 | $45.03 | $135,675 | Direct |
| Jun 22, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 62,500 | - | $0 | Direct |
| Feb 3, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 150,000 | - | $0 | Direct |
| Jun 2, 2025 |  MNMD Mind Medicine (MindMed) Inc. | Award(A) Stock Option (Right to Buy) | 500,000 | - | - | Direct |
| Dec 2, 2024 |  LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Restricted Stock Unit | 7,900 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 139,380 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 90,000 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 119,700 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 90,580 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Restricted Stock Unit | 15,090 | - | - | Direct |
| Oct 25, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Award(A) Retention Restricted Stock Units | 7,900 | - | - | Direct |
1-14 of 14 transactions
About Roberts Brandi
Roberts Brandi (SEC CIK 0001516354) files insider reports with the SEC as Chief Financial Officer of Definium Therapeutics, Inc. (DFTX) and Executive VP and CFO of Longboard Pharmaceuticals, Inc. (LBPH).
Signal8 holds 10 ownership filings by Roberts Brandi (1 Form 3, 9 Form 4), filed between Oct 29, 2024 and Sep 29, 2026. Those filings report 14 transactions, from Oct 25, 2024 to Sep 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Roberts Brandi's filings is in NEW YORK, NY.
Recent filings by Roberts Brandi
- Sep 25, 2026: Open-market sale of DFTX shares (Form 4, code S).
- Sep 14, 2026: Grant or award of DFTX shares (Form 4, code A).
- Aug 12, 2026: Grant or award of DFTX shares (Form 4, code A).
- Jun 25, 2026: Open-market sale of DFTX shares (Form 4, code S).
- Jun 22, 2026: Grant or award of DFTX shares (Form 4, code A).
Other insiders filing for Definium Therapeutics, Inc. (DFTX)
- Karlin Daniel, Chief Medical Officer
- Barrow Robert, Chief Executive Officer
- Wiley Matthew T., Chief Commercial Officer
- Sullivan Mark, Chief Legal Officer
- Vallone Carol A, Director
- Krebs Andreas, Director